By 
For those who contract herpes simplex in any of its forms, the virus is generally considered a lifetime sentence defined by unpredictable flareups and endless rounds of medication. However, a major treatment breakthrough from Australian research and product development company Synergy Pharmaceuticals suggests that herpes may be curable. News of this medical breakthrough could lead to a windfall for Synergy, but in addition to its impending success, the company is also tasked with overcoming criticism from many within the medical community.
A young company restores hope
Whereas previous drug trials focused on finding a vaccine for the herpes virus, Synergy Pharmaceuticals focused on finding a holistic solution for existing herpes patients, and the approach generated unprecedented results.
The company used a five-part treatment, the Combination Herpes Treatment, crafted from L-Lysine, Tribulus, Astragalus, Rhodiola, and a Unique Amino Formula. The special combination of natural ingredients generated T cells which helped break down herpes’ viral envelope and weakened the virus to the point of erasure. Essentially, the combination treatment prevented cell-to-cell infection and suppressed the virus’ overall activity.
Synergy Pharmaceuticals’ research showed a significant result in 72% of test cases. Patients involved in the study had been infected for several years and ingested the five core compounds as directed for six months.
The core combination proved to be more effective than traditional antiviral medications or any proposed vaccines. And since first unveiling the results of its initial study, Synergy Pharmaceuticals has made the core combination treatment available to the public and results have been equally promising.
However, with only a few years on the market, Synergy Pharmaceuticals is a relatively small fish in a very big ocean. The company is making substantial headway across the Australian and Australasian markets and gaining a foothold in a highly competitive pharmaceutical marketplace. But its groundbreaking cure, the first-ever natural treatment option for the herpes simplex virus, has invited scrutiny from many critics, including the major medical associations.
And naturally, there are concerns about Synergy Pharmaceuticals’ ability to meet global demand for its product as word spreads. These queries are understandable, but there’s a simple solution. To ramp up its capacity, Synergy will need to form strong partnerships across the European sector. And to reach a scalable level of sales for millions of consumers, more companies need to buy in and support Synergy’s business. In securing these partnerships, Synergy could take its business revenue to new heights and possibly quiet its critics.
The criticism stems not from ethical concerns about the drug’s effectiveness but from an industry-wide reluctance to embrace medications that aren’t pharmaceutical-based. It’s an age-old dispute, in which the medical community refuses to acknowledge the health impacts of natural treatments. The conflict is especially controversial when discussing a potential cure for the most prevalent viral disease. Understandably, critics like Josh Bloom come as no surprise given his longstanding employment with Wyeth and then Pfizer. What is more starting is considering Josh was himself a supporter and advocate for the Rational Vaccine study that was later brought under federal criminal investigation.
The (unsuccessful) race for a cure
Scrutiny aside, Synergy Pharmaceuticals has achieved something that many other companies have failed to do.
Vical Incorporated, a biopharmaceutical product developer, launched a clinical study in 2017 with the hopes of treating herpes simplex virus type 2 (HSV-2). The study seemed hopeful – it was double-blind, placebo-controlled, and randomized, and the study group was comprised of herpes patients that experienced 4-9 flareups in a given year. But in June 2018, Vical announced the study had failed. Study participants did not see a significant reduction in recurrences during the trial period. Sadly, based on the study’s disappointing results, Vical decided to terminate its entire HSV-2 program.
Vaccine and immunotherapy company Genocea launched its GEN-003 drug trial with the hopes of discovering a cure for genital herpes. But in September 2017, the GEN-003 program was shuttered, with Genocea cutting its workforce by roughly 40%. In an official press release, the company said it was “exploring strategic alternatives” to the GEN-003 program. Like Vical Incorporated, Genocea too had failed.
This left hope in the hands of Rational Vaccines, a medical research company that had announced a successful 2016 drug trial for a live vaccine, Theravax, which treated both HSV-1 and HSV-2. Rational Vaccines was the brainchild of Southern Illinois University professor William Halford, who’d been working on a herpes cure since 2007. Halford failed to muster up the financial support to fund his research, so he conducted drug trials without the approval of the FDA. Three of the patients in his trial had adverse reactions to the treatment and sued Rational Vaccines. Then, the FDA announced a criminal investigation into Rational Vaccines’ study and operations. So, despite Rational Vaccines’ breakthrough and the promise of its future work, progress was halted, and it seemed the medical industry as a whole had no way forward with a cure for herpes.
With so many highly publicized failures in recent years, it makes sense that critics would doubt Synergy Pharmaceuticals. But with successful research results and a consumer product on the market, the company is proving that this herpes treatment is the real deal.
Only time will tell how Synergy Pharmaceuticals and its stakeholders are impacted as the Combination Herpes Treatment becomes more widely available. However, one option could be a financial showdown with big pharmaceutical companies. If the giants double down on their antiviral approach, they could try to buy out Synergy to eliminate the threat to their businesses.
With so many highly publicized failures in recent years, it makes sense that critics would doubt Synergy Pharmaceuticals. But with successful research results and a consumer product on the market, the company is proving that this herpes treatment is the real deal. “While we have been faced with our fair share of challenges. All in all when offering something as revolutionary as what this is, it is to be expected.” CEO Simon Anderson.
Whatever happens, it’s quite possible that Synergy will do more than improve the lives of millions of customers – it could also cause a major shakeup in the pharmaceutical industry.
For more Information: www.synergy-pharmaceuticals
Media Details
Name: Simon Anderson
Company: Synergy Pharmaceuticals
Email: [email protected]
Comments